With the development of research on the complex aetiology of many diseases,
computational drug repositioning methodology has proven to be a shortcut to costly and …

The increase in presynaptic striatal dopamine is the main dopaminergic abnormality in
schizophrenia (SCZ). SCZ is primarily treated by modulating the activity of monoamine …

Clozapine is listed as one of the most effective antipsychotics and has been approved for
treating treatment-resistant schizophrenia (TRS); however, several type A and B adverse …

Schizophrenia (Sch) is a severe and widespread mental disorder. Antipsychotics (APs) of
the first and new generations as the first-line treatment of Sch are not effective in about a …

For most psychiatric diseases, pathogenetic concepts as well as paradigms underlying
neuropsychopharmacologic approaches currently revolve around neurotransmitters such as …

Schizophrenia is characterized by visual distortions in~ 60% of cases, and visual
hallucinations (VH) in~ 25–50% of cases, depending on the sample. These symptoms have …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

This review of commonly prescribed psychotropic drugs aims to update the clinician on
possible ophthalmic side effects that may include dry eye, diplopia, mydriasis, and cataracts …

Schizophrenia is a disorder that is characterized by delusions, hallucinations, disorganized
speech or behavior, and socio-occupational impairment. The duration of observation and …

Abstract Brexpiprazole (Rxulti®, Rexulti®) is an oral atypical antipsychotic agent approved
for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in …